6/18/2020 9:07:44 AM
Natera : First Patient Enrolls In Both CIRCULATE-Japan And BESPOKE CRC Trials Using Signatera MRD Testing
6/17/2020 1:08:09 PM
Natera Files Patent Suit Against Progenity
5/18/2020 9:06:00 AM
Natera, Illumina Settle Patent Infringement Action
4/14/2020 12:14:03 AM
Natera Prices $250 Million Convertible Senior Notes Due 2027
4/13/2020 7:13:20 AM
Natera Proposes To Offer $250 Mln Of Convertible Senior Notes Due 2027
4/13/2020 7:05:56 AM
Natera Expects Q1 Revenues Of $89 Mln - $91 Mln
1/27/2020 9:16:32 AM
Natera Files Suit Against ArcherDX For Infringement Of U.S. Patent No. 10,538,814
1/15/2020 8:44:15 AM
Natera Announces Agreement With National Cancer Center Japan To Launch CIRCULATE-IDEA Trial In Japan
1/13/2020 9:28:16 AM
Natera Reports New Early Priority Date CfDNA Patent, Files Suit Against CareDx
1/9/2020 9:07:48 AM
Natera To Evaluate Outcomes In 1,000 Signatera Patients With Stage II-III Colorectal Cancer
11/27/2019 8:22:35 AM
Natera Announces Results Of A Study Published In The Journal Of Prenatal Diagnosis
10/16/2019 10:32:33 PM
Natera Prices Underwritten Public Offering Of 5.71 Mln Shares At $35.00/shr
8/29/2019 9:21:06 AM
Natera Appoints Rowan Chapman To Its Board
5/9/2019 4:24:34 PM
Natera Q1 Loss/share $0.54 Vs. Loss $0.61 Year Ago
5/6/2019 11:57:39 AM
FDA Grants Breakthrough Device Designation To Natera's Signatera Test
4/17/2019 11:44:59 PM
Natera Announces Pricing Of Follow-On Offering Of 5.26 Mln Shares At $19/Shr